Pharmaceutical giant (NYSE: PFE) is trading near its lowest price in over a decade.
The company's revenue and profits ballooned during the pandemic on its COVID-19 vaccine and treatment. Then the balloon popped and the business contracted, sending investors running for the exits. Pfizer has become an interesting case of a well-known stock offering an outsized dividend yield.
Is this a classic yield trap -- an abnormally high yield with poor business fundamentals lurking beneath the surface? Or could it be a once-in-a-decade investment opportunity?
Source Fool.com